Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Wheeler SB, Kohler RE, Goyal RK, Lich KH, Lin CC, Moore A, Smith TW, Melvin CL, Reeder-Hayes K, Domino ME. Is medical home enrollment associated with receipt of guideline-concordant follow-up care among low-income breast cancer survivors? Med Care. 2013 Jun;51(6):494-502.
Bray JW, Zarkin GA, Davis KL, Mitra D, Higgins-Biddle JC, Babor TF. The effect of screening and brief intervention for risky drinking on health care utilization in managed care organizations. Med Care. 2007 Feb 28;45(2):177-82.
Mauskopf J. Industry responsibility in interactive computer modeling. Med Care. 1996 Dec 1;34(12 Suppl):DS165-72.
French MT, Mauskopf JA, Teague JL, Roland EJ. Estimating the dollar value of health outcomes from drug-abuse interventions. Med Care. 1996 Sep 1;34(9):890-910.
Mauskopf JA, Austin R, Dix LP, Berzon RA. Estimating the value of a generic quality-of-life measure. Med Care. 1995 Apr 1;33(4 Suppl):AS195-202.